Stock Scorecard



Stock Summary for BridgeBio Pharma Inc (BBIO) - $35.05 as of 3/28/2025 7:18:12 PM EST

Total Score

4 out of 30

Safety Score

44 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for BBIO

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BBIO

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BBIO

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BBIO

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BBIO (44 out of 100)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 6
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 5
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for BBIO

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug - BridgeBio Pharma ( NASDAQ:BBIO ) 3/27/2025 7:20:00 PM
Beyonttra™ ( acoramidis ) , the First Near-complete TTR Stabilizer ( ≥90% ) , Approved in Japan to Treat ATTR-CM - BridgeBio Pharma ( NASDAQ:BBIO ) 3/27/2025 11:00:00 AM
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy ( ATTR-CM ) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions 3/24/2025 11:30:00 AM
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy ( ATTR-CM ) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions - BridgeBio Pharma ( NASDAQ:BBIO ) 3/24/2025 11:30:00 AM
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 ) 3/21/2025 8:00:00 PM
BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt - BridgeBio Pharma ( NASDAQ:BBIO ) 2/26/2025 7:49:00 AM
BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt 2/26/2025 7:49:00 AM
BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt 2/24/2025 9:09:00 PM
BridgeBio Pharma ( BBIO ) Reports Q4 Loss, Tops Revenue Estimates 2/20/2025 1:55:00 PM
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update 2/20/2025 12:30:00 PM

Financial Details for BBIO

Company Overview

Ticker BBIO
Company Name BridgeBio Pharma Inc
Country USA
Description BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date 4/30/2025

Stock Price History

Last Day Price 35.05
Price 4 Years Ago 16.68
Last Day Price Updated 3/28/2025 7:18:12 PM EST
Last Day Volume 1,705,973
Average Daily Volume 3,408,157
52-Week High 39.47
52-Week Low 21.62
Last Price to 52 Week Low 62.12%

Valuation Measures

Trailing PE N/A
Industry PE 37.01
Sector PE 40.10
5-Year Average PE -9.08
Free Cash Flow Ratio 25.04
Industry Free Cash Flow Ratio 11.91
Sector Free Cash Flow Ratio 47.05
Current Ratio Most Recent Quarter 3.19
Total Cash Per Share 1.40
Book Value Per Share Most Recent Quarter -7.72
Price to Book Ratio 123.68
Industry Price to Book Ratio 8.86
Sector Price to Book Ratio 21.92
Price to Sales Ratio Twelve Trailing Months 31.20
Industry Price to Sales Ratio Twelve Trailing Months 88.85
Sector Price to Sales Ratio Twelve Trailing Months 27.78
Analyst Buy Ratings 9
Analyst Strong Buy Ratings 6

Share Statistics

Total Shares Outstanding 190,189,000
Market Capitalization 6,666,124,450
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -33.67%
Reported EPS 12 Trailing Months -2.88
Reported EPS Past Year -2.82
Reported EPS Prior Year -3.94
Net Income Twelve Trailing Months -438,860,000
Net Income Past Year -643,202,000
Net Income Prior Year -481,183,000
Quarterly Revenue Growth YOY 237.10%
5-Year Revenue Growth -26.45%
Operating Margin Twelve Trailing Months -3,763.00%

Balance Sheet

Total Cash Most Recent Quarter 266,324,000
Total Cash Past Year 434,884,000
Total Cash Prior Year 471,922,000
Net Cash Position Most Recent Quarter -1,452,992,000
Net Cash Position Past Year -1,291,845,000
Long Term Debt Past Year 1,726,729,000
Long Term Debt Prior Year 1,707,615,000
Total Debt Most Recent Quarter 1,719,316,000
Equity to Debt Ratio Past Year -3.64
Equity to Debt Ratio Most Recent Quarter -2.51
Total Stockholder Equity Past Year -1,354,257,000
Total Stockholder Equity Prior Year -1,254,617,000
Total Stockholder Equity Most Recent Quarter -1,229,922,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -456,325,000
Free Cash Flow Per Share Twelve Trailing Months -2.40
Free Cash Flow Past Year -529,026,000
Free Cash Flow Prior Year -425,815,000

Options

Put/Call Ratio 0.18
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.66
MACD Signal 0.16
20-Day Bollinger Lower Band 22.63
20-Day Bollinger Middle Band 31.10
20-Day Bollinger Upper Band 39.57
Beta 1.07
RSI 60.49
50-Day SMA 28.21
150-Day SMA 22.17
200-Day SMA 25.40

System

Modified 3/28/2025 6:46:22 PM EST